|
Introduction
The Breast Cancer Prevention Trial (BCPT) is designed to see whether taking the drug tamoxifen (Nolvadex®) can prevent breast cancer in women who are at an increased risk of developing the disease. The BCPT is also looking at whether taking tamoxifen decreases the number of heart attacks and reduces the number of bone fractures in these women.
The study began recruiting participants in April 1992 and closed enrollment in September 1997; 13,388 women ages 35 and older are enrolled. Researchers with the
National Surgical Adjuvant Breast and Bowel Project (NSABP)
are conducting the study in more than 300 centers across the United States and Canada. The study is funded by the National Cancer Institute (NCI), the United States' primary agency for cancer research.
Next Section > |
